Find a Research Expert

Experts
 Menu

Ken O'Byrne

Institution

Trinity College Dublin

Contact

Subjects

Medicine & Nursing

Biochemistry

Details
Publications 49
As first author 27
As last author 31
Unique topics 331
Collaborations 49
Sources 3
Are you Ken O'Byrne? Click here to provide feedback on your profile.
All
2019
2018
2017
2016
2015
2014
2013
2011
2010
Earlier
All
2019
2018
2017
2016
2015
2014
2013
2011
2010
Earlier

2019

First-line nivolumab plus ipilimumab in advanced non-small-cell lung cancer (CheckMate 568): Outcomes by programmed death ligand 1 and tumor mutational burden as biomarkers
2019

Nivolumab plus ipilimumab in non-small-cell lung cancer
2019

Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer
2018

Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials
2018

Combination therapy with histone deacetylase inhibitors (HDACi) for the treatment of cancer: Achieving the full therapeutic potential of HDACi
2018

Development and characterisation of a panel of phosphatidylinositide 3-kinase - mammalian target of rapamycin inhibitor resistant lung cancer cell lines.
2018

The prognostic role of circulating tumor cells (CTCs) in lung cancer
2017

Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: Overall survival data from the phase IIb LUX-Lung 7 trial
2017

Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small-cell lung cancer: Results from a British Thoracic Oncology Group randomised phase III trial
2017

Enrichment of circulating head and neck tumour cells using spiral microfluidic technology
2017

Modulating lysosomal function through lysosome membrane permeabilization or autophagy suppression restores sensitivity to cisplatin in refractory non-small-cell lung cancer cells.
2017

hSSB1 associates with and promotes stability of the BLM helicase
2017

hSSB1 phosphorylation is dynamically regulated by DNA-PK and PPP-family protein phosphatases
2016

A structural analysis of DNA binding by hSSB1 (NABP2/OBFC2B) in solution
2016

Activation and cleavage of SASH1 by caspase-3 mediates an apoptotic response
2016

HSSB1 (NABP2/OBFC2B) is regulated by oxidative stress
2016

In pursuit of synergy: An investigation of the PI3K/mTOR/MEK co-targeted inhibition strategy in NSCLC
2016

Nucleophosmin: From structure and function to disease development
2016

Promotion of a cancer-like phenotype, through chronic exposure to inflammatory cytokines and hypoxia in a bronchial epithelial cell line model.
2016

SASH1 mediates sensitivity of breast cancer cells to chloropyramine and is associated with prognosis in breast cancer
2016

Short term ex-vivo expansion of circulating head and neck tumour cells
2015

Vascular endothelial growth factor is an autocrine growth factor, signaling through neuropilin-1 in non-small cell lung cancer
2014

2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up.
2014

Chemotherapeutic compounds targeting the DNA double-strand break repair pathways: the good, the bad, and the promising.
2014

Functions and therapeutic roles of exosomes in cancer.
2014

The MyD88+ Phenotype Is an Adverse Prognostic Factor in Epithelial Ovarian Cancer.
2014

The establishment of an ISO compliant cancer biobank for Jordan and its neighboring countries through knowledge transfer and training.
2013

Generation and characterisation of Cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature.
2013

Genome stability pathways in head and neck cancers.
2013

Global analysis of serum microRNAs as potential biomarkers for lung adenocarcinoma.
2013

IL-23R is Epigenetically Regulated and Modulated by Chemotherapy in Non-Small Cell Lung Cancer.
2013

Long non coding RNAs (lncRNAs) are dysregulated in Malignant Pleural Mesothelioma (MPM).
2013

Prognostic and therapeutic relevance of FLIP and procaspase-8 overexpression in non-small cell lung cancer
2013

RanGTPase: A Candidate for Myc-Mediated Cancer Progression
2013

Targeting nuclear factor-kappa B to overcome resistance to chemotherapy.
2011

COX-Derived prostanoid pathways in gastrointestinal cancer development and progression: Novel targets for prevention and intervention
2011

Epigenetic Regulation of Glucose Transporters in Non-Small Cell Lung Cancer
2011

Epigenetics Underpinning the Regulation of the CXC (ELR+) Chemokines in Non-Small Cell Lung Cancer
2011

Modern operative and oncological outcome in oesophagel cancer
2011

Overexpression of the mammalian target of rapamycin (mTOR) and angioinvasion are poor prognostic factors in early stage NSCLC: a verification study.
2011

Receptor tyrosine kinases and their activation in melanoma.
2011

The role of epigenetics in resistance to cisplatin chemotherapy in lung cancer
2010

A single institution experience of streptozocin/fluorouracil combination chemotherapy: a case series.
2010

Differential pathologic variables and outcomes across the spectrum of adenocarcinoma of the esophagogastric junction.
2010

The role of prostacyclin synthase and thromboxane synthase signaling in the development and progression of cancer
2007

Lipoxygenase metabolism: roles in tumor progression and survival.
2007

Long-term outcomes following neoadjuvant chemoradiotherapy for esophageal cancer.
2006

(18)FDG uptake during induction chemoradiation for oesophageal cancer fails to predict histomorphological tumour response.
2006

Chemotherapy induced reversible posterior leukoencephalopathy syndrome.

These arethe3 unique sources for Ken O'Byrne's 49 publications. A single publication may appear in multiple sources. Click on a name or publication count to see the publications for a particular source.

Source #
Ireland -> Maynooth University 1
Ireland -> Trinity College Dublin 49
Ireland -> Trinity College Dublin -> PubMed 8

  1. Further insights

    Clicking through these tabs will give you a wealth of further insights into this expert through their commonly used topics, the evolution of their expertise, their collaborators and their publications.

  2. Details

    Here is a quick breakdown of this expert's publication history

  3. Contact

    If this is the expert you have been looking for, simply click here to make contact.